期刊文献+

米索前列醇对去势后大鼠骨保护素的影响

Effect of Misoprostol on Osteoprotegerin in the Bone of Ovariectomized Rats
下载PDF
导出
摘要 目的:通过给予去势后大鼠米索前列醇,了解米索前列醇对骨密度及成骨细胞分泌骨保护素 (Osteo protegerin, OPG)的影响。方法:鼠龄90 d的Wistar雌性大鼠共 30 只,分为正常对照组(A组)、去势组(B组)、去势给米索前列醇组(C组),C组去势后第2 d予以2 mg·kg-1·d-1剂量的米索前列醇灌胃,于术后28 d对各组的骨密度进行检测,同时取左侧胫骨干骺端观察骨保护素 mRNA水平的变化。结果: 骨密度检测结果显示 A组最高,C组次之,而B组最低,A组、B组、C组之间差异有显著性(P<0.05);骨保护素3组之间差别有显著性,C组最高,B组次之,A组最低(P<0.05)。结论: 米索前列醇可能通过刺激骨保护素的表达及分泌,来抑制去势后雌性大鼠骨量的丢失。 Objective: To investigated the influence of misoprostol on bone mineral density (BMD) and osteoprotegerin (OPG) in ovariectomized (OVX) rats. Methods: Thirty female Wistar rats aged 3 months were divided into three groups as Sham(A), OVX(B) and OVX+ misoprostol(C)group with 10 rats in each group. The group C treated orally 2 mg·kg -1 ·d -1 misoprostol for 28 days. All rats were sacrificed and the BMD of rats was measured by dual-energy X-ray Absorption, and reverse transcription-polymerase chain reaction (RT-PCR) examination which indicated the expression of OPG on mRNA level in tibial metaphyses. Results: The BMD of rats in group A was the highest one, while in group C was higher than that in group B, and there was a significant difference among the group A, B and C. There was a significant difference in OPG among the three groups as C>B>A in turn. Conclusion: Misoprostol can effectively prevent osteoporosis in ovariectomized rats by up-regulating OPG mRNA level and inhibiting osteoclastic bone resorption.
出处 《武汉大学学报(医学版)》 CAS 2005年第2期176-179,共4页 Medical Journal of Wuhan University
关键词 米索前列醇 骨密度 骨保护素 RT-PCR Misoprostol Bone Mineral Density Osteoprotegerin RT-PCR
  • 相关文献

参考文献8

  • 1Sonmez S, Mustafa BM, Ozer MK, et al. Effects of misoprostol on bone loss in ovariectomized rats. Prostaglandins & Other Lipid Mediators, 1999, 57: 113.
  • 2Mizuno A, Murakami A, Nakagawa N, et al. Structure of the mouse osteoclastogenesis inhibitory factor (OCIF) gene and its expression in embryogenesis. Gene, 1998, 215: 339.
  • 3Yana K, Tsuda E, Washida B, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor increased serum concentrations in protmenopausal women with osteoporisis. T Bone Miner Res, 1999,14:518.
  • 4Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokine from human fibroblast that specifically inhibits oateoclasteogenesis. Biochem Biophys Res Commun, 1997,234:137.
  • 5Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1997, 89:309.
  • 6Akatsy T, Murakami T, Nisbikawa M, et al. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem Biophy Res Commun, 1998, 253:229.
  • 7Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin(OPG):a mechanism by with OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology, 1998, 139(3):1 329.
  • 8Wong F, Massie D, Hsu P. Dose-dependent effects of oral misoprostol on renal function in alcoholic cirrhosis. Gastroenterology, 1994,106:658.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部